$479 Million is the total value of Sands Capital Ventures, LLC's 18 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 12.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PATH | UIPATH INC | $82,296,000 | -49.9% | 3,811,779 | 0.0% | 17.19% | -29.4% | |
| NU HOLDINGS LTD. | $70,536,000 | -17.7% | 9,136,835 | 0.0% | 14.74% | +16.0% | ||
| DASH | DOORDASH INC | $70,484,000 | -21.3% | 601,454 | 0.0% | 14.72% | +10.9% | |
| DICE THERAPEUTICS, INC. | $60,240,000 | -24.4% | 3,148,970 | 0.0% | 12.58% | +6.5% | ||
| SNOW | SNOWFLAKE INC | $49,176,000 | -32.4% | 214,621 | 0.0% | 10.27% | -4.6% | |
| SAMSARA, INC. | $43,450,000 | -43.0% | 2,712,256 | 0.0% | 9.08% | -19.7% | ||
| KRTX | KARUNA THERAPEUTICS, INC. | $33,966,000 | -3.2% | 267,895 | 0.0% | 7.10% | +36.4% | |
| New | CINCOR PHARMA, INC. | $16,663,000 | – | 950,000 | +100.0% | 3.48% | – | |
| ABOS | ACUMEN PHARMACEUTICALS, INC | $13,361,000 | -42.2% | 3,417,075 | 0.0% | 2.79% | -18.5% | |
| OLK | New | OLINK HOLDING AB | $7,515,000 | – | 425,514 | +100.0% | 1.57% | – |
| MASS | 908 DEVICES INC | $6,205,000 | -26.5% | 326,427 | 0.0% | 1.30% | +3.5% | |
| SAMSARA, INC. | $5,223,000 | -43.0% | 326,000 | 0.0% | 1.09% | -19.7% | ||
| TSHA | TAYSHA GENE THERAPIES INC | $4,726,000 | -44.0% | 724,873 | 0.0% | 0.99% | -21.2% | |
| TARS | TARSUS PHARMACEUTICALS INC | $4,373,000 | -25.2% | 260,000 | 0.0% | 0.91% | +5.4% | |
| RGEN | REPLIGEN CORP. | $4,240,000 | -29.0% | 22,544 | 0.0% | 0.89% | +0.1% | |
| CANDEL THERAPEUTICS, INC | $4,132,000 | -34.9% | 811,737 | 0.0% | 0.86% | -8.3% | ||
| SPRB | SPRUCE BIOSCIENCES INC | $1,582,000 | -54.9% | 787,007 | 0.0% | 0.33% | -36.3% | |
| ABSCI CORP. | $487,000 | +2.7% | 57,804 | 0.0% | 0.10% | +45.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UIPATH INC | 9 | Q3 2023 | 30.2% |
| DOORDASH INC | 9 | Q3 2023 | 19.6% |
| SNOWFLAKE INC | 9 | Q3 2023 | 14.4% |
| ACUMEN PHARMACEUTICALS, INC | 9 | Q3 2023 | 10.0% |
| 908 DEVICES INC | 9 | Q3 2023 | 1.8% |
| TARSUS PHARMACEUTICALS INC | 9 | Q3 2023 | 1.4% |
| TAYSHA GENE THERAPIES INC | 9 | Q3 2023 | 2.0% |
| CANDEL THERAPEUTICS, INC | 9 | Q3 2023 | 1.3% |
| SPRUCE BIOSCIENCES INC | 9 | Q3 2023 | 0.7% |
| ABSCI CORPORATION | 9 | Q3 2023 | 0.1% |
View Sands Capital Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-15 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-09 |
View Sands Capital Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.